comparing petosemtamab and pembrolizumab in hnscc with existing therapies
Published 3 weeks ago • 62 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
0:37
tils prolong pfs compared with pembrolizumab in advanced melanoma
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
1:52
safety of bca101, an egfr/tgfβ inhibitor, with pembrolizumab in hnscc
-
0:39
predicting responses to immunotherapy in head and neck cancer
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
5:01
patient selection for pembrolizumab in hnscc
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
1:32
dr. cohen on immunotherapy combinations in head and neck cancer
-
2:26
sd-101 plus pembrolizumab for hnscc
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
11:47
pembrolizumab in hnscc
-
2:00
durvalumab plus danvatirsen for r/m hnscc: exciting scores data
-
2:12
real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic uc
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma